SCHEMBL5986924

SCHEMBL5986924

CC(=O)NCc1ccc(C(C)Cl)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 3/20 0.56
▸ RAB9A P51151 3/20 0.56
▸ ALDH1A1 P00352 3/20 0.56
▸ MAPT P10636 2/20 0.56
▸ POLB P06746 1/20 0.56
▸ HDAC1 Q13547 2/20 0.53
▸ HDAC6 Q9UBN7 1/20 0.53
▸ SMN1; SMN2 Q16637 2/20 0.50
▸ MEN1 O00255 2/20 0.50
▸ GAA P10253 1/20 0.48
▸ HDAC3 O15379 1/20 0.45
▸ HDAC2 Q92769 1/20 0.45
▸ ADAMTS4 O75173 1/20 0.45
▸ MMP13 P45452 1/20 0.45
▸ L3MBTL1 Q9Y468 1/20 0.44
▸ ADRB2 P07550 1/20 0.43
▸ ADRB1 P08588 1/20 0.43
▸ ADRB3 P13945 1/20 0.43
▸ VHL P40337 1/20 0.43
▸ NPC1 O15118 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13104785 0.85 RAB9A (0.61) KMT2ARAB9AALDH1A1MAPTPOLB
SCHEMBL5988669 0.84 KMT2A (0.58) KMT2ARAB9AALDH1A1MAPTPOLB
SCHEMBL12133623 0.82 KMT2A (0.76) KMT2ARAB9AALDH1A1MAPTPOLB
SCHEMBL23627121 0.81 KMT2A (0.54) KMT2ARAB9AALDH1A1MAPTPOLB
SCHEMBL12646172 0.79 KMT2A (0.56) KMT2ARAB9AALDH1A1MAPTPOLB
SCHEMBL10202712 0.78 KMT2A (0.59) KMT2ARAB9AALDH1A1MAPTPOLB
SCHEMBL12134066 0.78 ERCC1 (0.62) KMT2ARAB9AALDH1A1MAPTPOLB
SCHEMBL14853576 0.78 KMT2A (0.59) KMT2ARAB9AALDH1A1MAPTPOLB
SCHEMBL196487 0.77 KMT2A (0.70) KMT2ARAB9AALDH1A1MAPTPOLB
SCHEMBL5987795 0.77 MAPT (0.68) KMT2ARAB9AALDH1A1MAPTPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060167014-A1 Piperazine compounds and medicinal use thereof MITSUBISHI PHARMA CORPORATION 2006-07-27 — — US disclosed
EP-1029851-B1 PIPERAZINE COMPOUNDS AND MEDICINAL USE THEREOF MITSUBISHI PHARMA CORP (JP) 2005-04-20 — — EP disclosed
CN-1145609-C Piperazine compounds and medical use thereof ������ҩ��ʽ���� 2004-04-14 — — CN disclosed
US-20030055064-A1 Piperazine compounds and medicinal use thereof MITSUBISHI PHARMA CORPORATION 2003-03-20 — — US disclosed
US-20030018034-A1 Piperazine compounds and medicinal use thereof MITSUBISHI PHARMA CORPORATION 2003-01-23 — — US disclosed
US-6455528-B1 TUMOR NECROSIS FACTOR ANTAGONIST AND/OR INTERLEUKIN PROMOTER; ANTIALLERGENS, ANTIINFLAMMATORY AGENTS; AUTOIMMUNE DISEASE TREATMENT MITSUBISHI PHARMA CORPORATION (JP) 2002-09-24 — — US disclosed
CN-1281438-A Piperazine compounds and their use as pharmaceuticals EFUKU CO LTD (JP) 2001-01-24 — — CN disclosed
EP-1029851-A1 PIPERAZINE COMPOUNDS AND MEDICINAL USE THEREOF YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) 2000-08-23 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030055064-A1 Piperazine compounds and medicinal use thereof TNF, IL5, CCR10 KMT2A 2109/4885RAB9A 1867/4885ALDH1A1 710/4885
US-20030018034-A1 Piperazine compounds and medicinal use thereof TNF, IL5, CCR10 KMT2A 2049/4885RAB9A 1914/4885ALDH1A1 788/4885
US-20060167014-A1 Piperazine compounds and medicinal use thereof TNF, CCR10, RELA KMT2A 1815/4885RAB9A 752/4885ALDH1A1 1148/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback